和黄医药:联合奥希替尼获批 赛沃替尼迎来重磅适应症扩展

中金公司
03 Jul

公司近况6 月30 日,公司公告赛沃替尼和奥希替尼联合疗法获得国家药监局批准,用于治疗EGFR突变且EGFR TKI治疗进展后伴MET扩增的局部晚期或转移性非鳞状非小细胞肺癌患者,此项批准亦将触发一项来自阿斯利康的1,100万美元的里程碑付款。评论该适应症为赛沃替尼目前获批的最大适应症。根据公司公告:美国和欧洲的非小细胞肺癌患者中约有10-25%存在EGFR突变,而亚洲患者中该比例则高达30-40...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10